BOTHELL, WA and VANCOUVER, May 28, 2013 /CNW/ - OncoGenex
Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott
Cormack, President and Chief Executive Officer, will provide a
corporate presentation at the Jefferies 2013 Healthcare Conference on
Tuesday, June 4 , 2013 at 8:00 a.m. ET at the Grand Hyatt Hotel in New
A live audio webcast can be accessed through the Investor Relations page
of the OncoGenex website at www.oncogenex.com. The webcast replay will be archived for 60 days.
OncoGenex is a biopharmaceutical company committed to the development
and commercialization of new therapies that address treatment
resistance in cancer patients. OncoGenex has a diverse oncology
pipeline, with each product candidate having a distinct mechanism of
action and representing a unique opportunity for cancer drug
development. OncoGenex and Teva Pharmaceutical Industries Ltd. have
entered a global collaboration and license agreement to develop and
commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is
currently in Phase 3 clinical development as a treatment in men with
metastatic castrate-resistant prostate cancer and in patients with
advanced, unresectable non-small cell lung cancer. OGX-427 is in Phase
2 clinical development and OGX-225 is currently in pre-clinical
development. More information is available at www.OncoGenex.com.
SOURCE: OncoGenex Pharmaceuticals, Inc.
For further information:
Investor Relations Contact: